Napro-A Plus 375is a tablet containing a combination of two active ingredients:
- Naproxen Sodium BP: 375 mg (a non-steroidal anti-inflammatory drug - NSAID)
- Esomeprazole BP:20 mg (a proton pump inhibitor - PPI)
It is manufactured by ACME Laboratories Ltd.
Indications:
Napro-A Plus (Naproxen & Esomeprazole) is indicated for the treatment of the signs and symptoms of:
- Osteoarthritis (OA)
- Rheumatoid arthritis (RA)
- Ankylosing spondylitis (AS)
- Dysmenorrhoea (painful menstruation)
It is also used to decrease the risk of developing gastric ulcers in patients at risk for developing NSAID-associated gastric ulcers.
Dosage and Administration:
The usual recommended dose for adults is one tablet twice daily.
- The tablet must be swallowed whole with water and should not be split, chewed, crushed, or dissolved.
- Napro-A Plus should be taken at least 30 minutes before a meal.
Dosage for specific conditions:
- Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis: One tablet (either 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole) twice daily.
- Juvenile Idiopathic Arthritis in Adolescent Patients 12 Years of Age & Older:
- Weight greater than 50 kg: Same as adult dose.
- Weight 38 kg to less than 50 kg: One tablet twice daily of 375 mg naproxen/20 mg esomeprazole.
Your doctor will determine the appropriate dosage and duration of treatment based on your condition and response.
Important Notes:
- Napro-A Plus is not recommended for the initial treatment of acute pain because the absorption of naproxen is delayed compared to other naproxen-containing products.
- The lowest effective dose should be used for the shortest possible duration consistent with individual patient treatment goals.
- The combination of Naproxen and Esomeprazole with other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the cumulative risk of serious NSAID-related adverse events.
Please consult your doctor for specific instructions and guidance regarding the use of Napro-A Plus 375.
Comment